Press coverage about Axovant Sciences (NASDAQ:AXON) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Axovant Sciences earned a coverage optimism score of 0.01 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.2390897604877 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have recently weighed in on the stock. Oppenheimer lowered shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 26th. Evercore ISI restated an “outperform” rating and set a $9.00 price objective (down previously from $30.00) on shares of Axovant Sciences in a research report on Tuesday, September 26th. ValuEngine lowered shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Piper Jaffray Companies lowered shares of Axovant Sciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $32.00 to $9.00 in a research report on Tuesday, September 26th. Finally, UBS Group lowered shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. Axovant Sciences presently has an average rating of “Hold” and a consensus price target of $14.14.

Axovant Sciences (AXON) traded down $0.03 during mid-day trading on Monday, reaching $2.03. 1,118,400 shares of the company’s stock were exchanged, compared to its average volume of 3,213,931. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 52 week low of $2.00 and a 52 week high of $27.98. The stock has a market capitalization of $235.89 and a price-to-earnings ratio of -0.88.

Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). analysts forecast that Axovant Sciences will post -2.15 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Insider Buying and Selling by Quarter for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with's FREE daily email newsletter.